Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relapsing-remitting

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    297 result(s) found for: Relapsing-remitting. Displaying page 4 of 15.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001422-25 Sponsor Protocol Number: ITA-BGT-12-10389 Start Date*: 2013-06-11
    Sponsor Name:Biogen Idec Italia S.r.l.
    Full Title: Single country study assessing cognition in Relapsing Remitting Multiple Sclerosis patients treated with BG00012
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012716-40 Sponsor Protocol Number: CO-200-201 Start Date*: 2009-12-31
    Sponsor Name:Peptimmune Inc.
    Full Title: The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel,...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) CZ (Completed) DE (Completed) FR (Ongoing) PL (Prematurely Ended) SK (Completed) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003037-32 Sponsor Protocol Number: 27178 Start Date*: 2007-09-11
    Sponsor Name:Merck Serono International SA
    Full Title: A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® Ne...
    Medical condition: Relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.0 10063399 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) EE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002470-31 Sponsor Protocol Number: MT-1303-E04 Start Date*: 2012-10-29
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered f...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed) CZ (Completed) HU (Completed) FI (Completed) BE (Completed) IT (Completed) PL (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005450-23 Sponsor Protocol Number: MS-LAQ-302 Start Date*: 2008-03-17
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad...
    Medical condition: Esclerosis Múltiple Remitente Recurrente (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) CZ (Completed) IT (Completed) SK (Completed) LT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003936-50 Sponsor Protocol Number: 28063 Start Date*: 2008-03-10
    Sponsor Name:Merck Serono International S.A.
    Full Title: Estudio en fase II, multicéntrico, aleatorizado, a doble ciego, con cuatro brazos y controlado frente a placebo, para evaluar, mediante RM frecuentes, la seguridad, tolerabilidad y eficacia de tres...
    Medical condition: Esclerosis múltiple recidivante Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) NL (Completed) BE (Completed) SE (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) LT (Restarted) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004334-41 Sponsor Protocol Number: LAQ/5063OL Start Date*: 2006-02-10
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: An active extension of LAQ/5062 study. A multinational, multicenter, randomized, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3 mg and 0.6 m...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) ES (Completed) DE (Completed) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002283-25 Sponsor Protocol Number: EMR200575-001 Start Date*: 2013-12-18
    Sponsor Name:Merck KGaA
    Full Title: A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copax...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IT (Completed) GB (Completed) FI (Completed) GR (Completed) ES (Completed) BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004935-18 Sponsor Protocol Number: GNC-004 Start Date*: 2017-04-12
    Sponsor Name:GeNeuro SA
    Full Title: A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006465-16 Sponsor Protocol Number: rhGH in MS Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024017-31 Sponsor Protocol Number: CFTY720DIT02 Start Date*: 2011-03-15
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000674-31 Sponsor Protocol Number: CFTY720DDE15TS Start Date*: 2012-08-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®
    Medical condition: RNFLT in Patients with relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001055-12 Sponsor Protocol Number: BIIT0212 Start Date*: 2015-05-28
    Sponsor Name:Biogen Idec Italia S.r.l.
    Full Title: Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-l...
    Medical condition: Patients with relapsing remitting multiple sclerosis (RRMS) treated with interferoneβ, suffering from flu-like syndrome (FLS).
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002201-11 Sponsor Protocol Number: BIIT0215 Start Date*: 2015-12-10
    Sponsor Name:BIOGEN IDEC ITALIA S.R.L.
    Full Title: Multicenter interventional Phase IV study for the assessment of the effects on patient’s satisfaction of Plegridy (pre-filled pen) in subjects with relapsing-remitting multiple sclerosis unsatisfie...
    Medical condition: Subjects with relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008065-35 Sponsor Protocol Number: TYNERGY Start Date*: 2009-03-13
    Sponsor Name:BiogenIdec A/S
    Full Title: A multi-centre and prospective trial to evaluate the effects on mul-tiple sclerosis related fatigue during treatment with Tysabri® in patients with relapsing remitting multiple sclerosis over the c...
    Medical condition: Mutiple sclerosis related fatigue in subjects with relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10016256 Fatigue LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001515-20 Sponsor Protocol Number: 12971/16 Start Date*: 2016-10-20
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS IN PERIPHERAL BLOOD FROM RRMS PATIENTS
    Medical condition: RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000365-19 Sponsor Protocol Number: CFTY720D2301 Start Date*: 2005-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo ...
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) CZ (Completed) DE (Completed) SK (Completed) FI (Completed) HU (Completed) GR (Completed) IE (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003884-71 Sponsor Protocol Number: LPS13649 Start Date*: 2015-02-05
    Sponsor Name:Genzyme Corporation
    Full Title: A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002667-34 Sponsor Protocol Number: WA39085 Start Date*: 2020-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE...
    Medical condition: Relapsing-remitting multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005972-42 Sponsor Protocol Number: 27571 Start Date*: 2007-06-12
    Sponsor Name:Merck Serono International SA
    Full Title: A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Int...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 11 04:51:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA